Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...
One of the world’s leading artificial intelligence companies has implored the industry to pause development on AI, because the latest models could be reaching a tipping point where they become capable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results